| Authors: |
Babu EM; Sanofi UK, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK., Fermahan S; Sanofi UK, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK., Bowen J; Sanofi UK, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK., Arnold K; IQVIA Ltd., The Point, 37 North Wharf Rd, Paddington, London, W2 1AF, UK., Broe A; IQVIA Ltd., The Point, 37 North Wharf Rd, Paddington, London, W2 1AF, UK., Lay-Flurrie S; IQVIA Ltd., The Point, 37 North Wharf Rd, Paddington, London, W2 1AF, UK., Matsakidis P; IQVIA Ltd., The Point, 37 North Wharf Rd, Paddington, London, W2 1AF, UK., Chetty M; Sanofi UK, 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT, UK. mersha.chetty@sanofi.com., Pawlyn C; The Institute of Cancer Research, London, SM2 5NG, UK.; Royal Marsden Hospital NHS Foundation Trust, London, SM2 5TP, UK. |
